Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-blind, Randomized, Placebo-controlled Clinical Trial to Assess the Efficacy and Safety of R051619 (Cisapride Oral Suspension 0.2mg/kg q.i.d) for the Treatment of Feeding Intolerance in Premature Infants

NCT01281566 is registered in ClinicalTrials.gov with Johnson & Johnson Pharmaceutical Research & Development, L.L.C. as lead sponsor.

NCT NCT01281566
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01281566 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-blind, Randomized, Placebo-controlled Clinical Trial to Assess the Efficacy and Safety of R051619 (Cisapride Oral Suspension 0.2mg/kg q.i.d) for the Treatment of Feeding Intolerance in Premature Infants
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase
Phase 4
Overall status
Terminated
Start date
March 31, 2003
Completion date
July 31, 2003
Enrollment
8 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

infant, newborn, infant, premature